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Abstract 
The mechanism of progression from ductal carcinoma in situ (DCIS) to invasive ductal car-
cinoma (IDC) remains largely unknown. We compared gene expression in tumors with 
simultaneous DCIS and IDC to decipher how diverse proteins participate in the local invasive 
process. 
Twenty frozen tumor specimens with concurrent, but separated, DCIS and IDC were mi-
crodissected and evaluated. Total RNA was extracted and microarray analysis was performed 
using Affymetrix GeneChip® Human Gene 1.0 ST Arrays. Microarray data were validated by 
quantitative  real  time  reverse  transcription-PCR  (qRT-PCR)  and  immunohistochemistry. 
Controls included seven pure in situ carcinomas, eight fragments from normal breast tissue, 
and a series of mouse breast carcinomas (MMTV-PyMT).  
Fifty-six genes were differentially expressed between DCIS and IDC samples. The genes 
upregulated in IDC samples, and probably associated with invasion, were related to the ep-
ithelial-mesenchymal transition (ASPN, THBS2, FN1, SPARC, and COL11A1), cellular adhesion 
(GJB2), cell motility and progression (PLAUR, PLAU, BGN, ADAMTS16, and ENPP2), extracellular 
matrix degradation (MMP11, MMP13, and  MMP14), and growth/proliferation (ST6GAL2). 
qRT-PCR confirmed the expression patterns of ASPN, GJB2, ENPP2, ST6GAL2, and TMBS10. 
Expression of the ASPN and GJB2 gene products was detected by immunohistochemistry in 
invasive carcinoma foci. The association of GJB2 protein expression with invasion was con-
firmed by qRT-PCR in mouse tumors (P < 0.05).  
Conclusions: The upregulation of ASPN and GJB2 may play important roles in local invasion 
of breast ductal carcinomas. 
Key  words:  breast  cancer,  in  situ  ductal  carcinoma,  invasive  ductal  carcinoma,  epitheli-
al-mesenchymal transition, ASPN, GJB2. 
INTRODUCTION 
Invasive ductal carcinoma (IDC) of the breast is a 
heterogeneous disease with a variety of histological 
subtypes. Tumor cell invasion is a complex process 
and the mechanisms controlling the transition from 
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ductal carcinomas in situ (DCIS) to IDC still remain 
unclear,  despite  research  in  recent  years.  Initial 
pathological studies suggest that IDC is preceded by 
DCIS, “atypical ductal hyperplasia”, and “usual duc-
tal  hyperplasia”  (1).  The  current  hypothesis  is  that 
genetic changes modulating invasiveness are present 
in cells even before they  acquire DCIS morphology 
(2-4). Furthermore, not all in situ lesions become in-
vasive, some IDCs are not associated with DCIS and, 
thus, the mechanisms of invasion in breast carcinomas 
remain unclear.  
Gene  expression  profiling  using  microarray 
technology  has  allowed  for  major  advances  in  the 
classification  of  breast  cancers.  Although  DCIS  ac-
counts for 15-40% of all diagnosed breast cancers (5), 
transcriptome studies of DCIS have proven difficult. 
Only a few studies with small sample numbers have 
compared the gene expression patterns of DCIS with 
those of IDC (2, 3, 6-10). Furthermore, only a few of 
the studies included breast carcinomas in which sim-
ultaneous DCIS and IDC components were separated 
and compared (2, 3, 7, 8). Although few coincidences 
of specific genes occurred in these studies, it is sug-
gested that upregulation of IDC genes is associated 
with  epithelial-mesenchymal  transition  (EMT),  cell 
motility,  extracellular  matrix  degradation,  and 
growth/proliferation. Since these studies are incom-
plete, further work in this area is needed to under-
stand the molecular mechanisms of cell invasion in 
this form of neoplasia.  
In  the  current  study,  we  identified  genes  that 
were  differentially  expressed  in  IDC  and  DCIS  by 
analyzing  tumors  containing  simultaneously  sepa-
rated foci with both components. Our results demon-
strate that the ASPN and GJB2 genes would have an 
important role in the mechanism of progression from 
DCIS to local invasion in breast carcinomas. 
MATERIALS AND METHODS 
Patients and tumor samples  
This study was conducted according to the Dec-
laration of Helsinki principles with approval by the 
ethics committee of the Institut de Recerca, Hospital 
de la Santa Creu i Sant Pau, Autonomous University, 
Barcelona,  Spain.  Twenty  human  breast  carcinomas 
containing DCIS and IDC lesions (matched samples) 
were  collected  prospectively  at  the  Department  of 
Pathology  at  Hospital  de  la  Santa  Creu  i  Sant  Pau 
between 2006 and 2010. In addition, seven pure DCIS 
samples and eight normal breast tissue samples were 
retrospectively selected as controls. Immediately after 
surgery, a portion of each tumor was rapidly embed-
ded in OCT (Tissue-Tek, Sakura, Europe, Alphen aan 
den Rijn, The Netherlands) and frozen using a histo-
bath  (Thermo  Shandon,  Pittsburgh,  PA,  USA).  The 
remaining tumor tissues were fixed in buffered 10% 
formalin and fixed in paraffin. H&E staining was used 
for pathological diagnosis of sections and tumor clas-
sification and grading was performed using standard 
methods. Clinical-pathological data are summarized 
in Table 1. 
 
Table 1. Main clinicopathological characteristics of patients 
and tumors.  
Age  ≥55  11 (55%) 
  <55  9 (45%) 
Tumor size (cm)  <2  4 (20%) 
  2-5  14 (70%) 
  >5  2 (10%) 
Lymph node metastasis  Positive  8 (40%) 
  Negative  12 (60%) 
Histological grade   I  3 (15%) 
  II  8 (40%) 
  III  9 (45%) 
Mitosis (sq mm/10)  <7  9 (45%) 
  7-13  5 (25%) 
  >13  6 (30%) 
Nuclear atypia  1  1 (5%) 
  2  5 (25%) 
  3  14 (70%) 
Tumor necrosis  Positive  8 (40%) 
  Negative  12(60%) 
Lymphatic invasion  Positive  5 (25%) 
  Negative  15 (75%) 
DCIS  >10%  15 (75%) 
  <10%  5 (25%) 
Estrogen receptors  Positive  17 (85%) 
  Negative  3 (15%) 
Progesterone receptors  Positive  9 (45%) 
  Negative  11 (55%) 
Her-2/neu  Positive   13 (65%) 
  Negative  7 (35%) 
Immunohistochemical subtype  HR+/Her 2 -*  10 (50%) 
  HR+/Her2+  7 (35%) 
  HR-/Her2+  2 (10%) 
  HR-/Her2-  1 (5%) 
* HR= Hormone receptors (either estrogen and or progesterone 
receptors); Her= HER2/neu; +=positive;-=negative 
 
 
RNA isolation 
Dissection  of  independent  DCIS  and  IDC  foci 
was done after examination of an H&E stained section 
of the OCT-embedded frozen tumor. Although DCIS 
and  IDC  were  independently  isolated,  associated 
stroma would be mixed with each tumor component.  Journal of Cancer 2012, 3 
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This limitation was lately overcome by the immuno-
histochemical detection and visualization of the can-
didate-gene products. 
Total RNA was isolated from selected areas of 
frozen  tissue  using  TRIzol  Reagent  (Invitrogen, 
Carlsbad,  CA,  USA)  and  purified  using  an  RNeasy 
Mini  Kit (QIAGEN, Hilden, Germany) according to 
manufacturers’  instructions.  RNA  was  resuspended 
in 14 µl RNase-free H2O  and stored at  -80°C. RNA 
concentrations and quality were determined using a 
NanoDrop apparatus (Thermo Fisher Scientific, Wil-
mington, DE, USA) and RNA integrity numbers (RIN) 
were analyzed using a RNA 6000 Nano LabChip Kit 
(Agilent Technologies, Boeblingen, Germany) with a 
Agilent 2100 Bioanalyzer according to the manufac-
turer’s instructions. 
Microarray analysis 
Microarray  analysis  was  performed  using 
Affymetrix GeneChip® Human Gene 1.0 ST Arrays 
(Affymetrix, Santa Clara, CA, USA) that consists of 
approximately  764,885  probe  sets  with  a  resolution 
number of 26 probes per gene, covering over 28,869 
genes.  The  entire  process  was  performed  following 
the Affymetrix instructions. Briefly, double-stranded 
cDNA was synthesized by a chimerical oligonucleo-
tide with oligo-dT and T7 RNA polymerase. The am-
plification  and  labeling  processes  were  monitored 
using a GeneChip® Eukaryotic Poly-A RNA Control 
Kit (Affymetrix) with exogenous positive controls that 
were spiked into the total RNA before cDNA synthe-
sis.  In  all  cases,  25  µg  of  each  biotinylated  cRNA 
preparation was fragmented and placed in hybridiza-
tion  cocktail  containing  biotinylated  hybridization 
controls (GeneChip® Expression Hybridization Con-
trols,  Affymetrix).  Samples  were  hybridized  onto  a 
GeneChip® Human Gene 1.0 ST Array at 45°C with 
60  rpm  for  17  hours  in  a  Hybridization  Oven  640 
(Affymetrix).  Microarray  scanned  images  were  ob-
tained with a GeneChip Scanner 3000 7G (Affymetrix) 
using  the  default  settings.  Images  were  visually  in-
spected to eliminate hybridization artifacts.  
Images  were  analyzed  with  R/Bioconductor 
software using the Oligo (11) and LIMMA packages 
(12).  Adjustment  for  multiple  tests  was  performed 
using Benjamini-Hochberg False Discovery Rate cor-
rection  (13).  Further  information  on  the  genes  was 
obtained  from  GeneCards  (http://www.genecards. 
org)  and  NCBI  databases  (http://www.ncbi.nlm. 
nih.gov).  Functional  annotation  was  performed  by 
uploading the resulting gene list onto DAVID (Data-
base  for  Annotation,  Visualization  and  Integrated 
Discovery,  http://david.abcc.ncifcrf.gov)  using  the 
GOTERM  database.  Genes  were  mapped  to 
KEGG-pathways  and  scored  according  to  P  values 
(EASE  Score,  modified  Fisher’s  exact  test)  and  cor-
rected  for  multiple  testing  according  to  the  Benja-
mini-Hochberg False Discovery Rate correction.  
Hierarchical clustering 
Unsupervised clustering analysis was performed 
using an average-linkage hierarchical clustering of a 
centered  correlation  similarity  matrix  of  DCIS  and 
IDC samples with 253 genes from the intrinsic gene 
list previously described (14). Genes were filtered and 
visualized,  using  GeneCluster  3.0  and  TreeView 
software, respectively.  
Reverse transcription and qRT-PCR 
Reverse transcription was performed using 1 μg 
of  total  RNA  extracted  from  each  of  20  matched 
DCIS/IDC samples, 7 pure DCIS, and 8 normal breast 
tissue  samples  using  the  High-Capacity  cDNA  Re-
verse  Transcription  Kit  (Applied  Biosystems,  Foster 
City, CA, USA). To analyze gene expression patterns, 
qRT-PCR  was  performed  using  specific  TaqMan 
probes  (Applied  Biosystems)  for  ASPN 
(Hs00214385_m1),  TMSB10  (Hs00363670_m1),  KRT5 
(Hs00361185_m1),  GJB2  (Hs00955889_m1),  ENPP2 
(Hs00196470_m1),  and  ST6GAL2  (Hs00383541_m1). 
qRT-PCR was performed according to the manufac-
turer’s instructions using a 7500 Real Time PCR Sys-
tem  (Applied  Biosystems).  Expression  levels  were 
measured in triplicate from each cDNA dilution. Rel-
ative gene expression was performed according to the 
comparative  Ct (ΔΔCt) method using  mitochondrial 
ribosome  protein  L19  (MRPL19)  as  an  endogenous 
control. 
Immunohistochemistry (IHC) 
Tissue microarrays (TMAs) were prepared from 
formalin-fixed  paraffin-embedded  tissues  obtained 
from three representative areas of each tumor. Tissue 
cores with 1 mm diameters were precisely arrayed in 
a paraffin block using a tissue microarray workstation 
(Beecher Instruments, Sun Prairie, WI, USA). For each 
TMA, H&E-stained slides were prepared to confirm 
the presence of the original selected tumor areas. Se-
rial, 5-m thick sections were stained using the EnVi-
sion method (DAKO, Glostrup, Denmark). Details of 
antibody  and  immunostaining  conditions  are  sum-
marized in Table 2. Tumors were scored according to 
the  intensity  of  cytoplasmic  or  nuclear  staining  as 
positive or negative (no staining or questionable sig-
nal  intensities).  All  immunohistochemical  results 
were  evaluated  separately  by  two  pathologists  (GP 
and  EL)  and  discordant  results  were  reviewed  to 
achieve agreement.  Journal of Cancer 2012, 3 
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Table 2. Primary Antibodies and other conditions for immunohistochemical analysis 
Antibody  Clone  Dilution  Supplier  Pretreatment 
ER  SP11  1:1*  Dako  PT link pH 9. 
PR  PgR636  1:1*  Dako  PT link pH 9. 
Ki-67  MIB-1  1:1*  Dako  PT link pH 6. 
Cam 5.2   Cam 5.2  1:2*  Dako  PT link pH 6. 
CK 5/6   D5/16 B4  1:1*  Dako  PT link pH 9. 
Vimentin  V9, Dako  1:1*  Dako  PT link pH 9. 
Asporin (ASPN)  Polyclonal  1:200  Covalab  PT link pH 9. 
 Connexin 26 (GJB2)  Polyclonal  1:10  Antibodies-online.com  PT link pH 6. 
ST6GAL2  Polyclonal  1:20  Sigma  PT link pH 6. 
Herceptest  Polyclonal  1:1*  Dako  HerceptestTM for Automated Link Platforms 
* Pre-diluted Ab 
 
Mouse tumor samples 
Animal  protocols  used  in  this  study  were  ap-
proved  by  the  Institutional  Animal  Care  and  Use 
Committee of the Institut de Recerca, Hospital de la 
Santa Creu i Sant Pau. Mouse tumor  samples  were 
kindly  provided  by  Dr.  Blanco-Vaca  (Sant  Pau  Re-
search  Institute,  Barcelona,  Spain).  MMTVPyMTTg 
mice express high levels of the transforming oncogene 
polyoma  virus  middle  T  antigen  (PyMT)  under  the 
control  of  the  mouse  mammary  tumor  virus  long 
terminal  repeat  promoter,  which  specifically  directs 
expression to the mammary epithelium. Mice spon-
taneously  develop  widespread  multifocal  adeno-
mas/DCIS at 8 weeks and invasive/metastatic carci-
nomas  at  13  weeks.  The  similarities  between  the 
PyMT  model  and  human  breast  cancer  have  been 
validated  by  histological  studies  demonstrating  a 
striking similarity between PyMT carcinogenesis and 
various  stages  of  human  ductal  carcinoma  progres-
sion (15). Genotyping was performed as indicated at 
Jackson  Laboratories,  Bar  Harbor,  ME,  USA.  Gene 
expression  of  mouse  tissues  was  performed  as  de-
scribed above for human tissues.  
Statistical analyses  
Differences  among  groups  were  analyzed  for 
statistical  significance  with  non-parametric 
Mann-Whitney  U  tests  or  by  one-way  analysis  of 
variance (ANOVA) using SPSS Statistics 18 software 
(Chicago,  IL,  USA).  In  addition,  when  the  variance 
was  not  homogeneous,  we  used  the  Kruskal-Wallis 
test. Results are expressed as means ± SE and differ-
ences were considered to be significant if P <0.05. 
RESULTS 
Tissue selection and clinical-pathological data 
Twenty breast cancer patients with tumors con-
taining simultaneous foci of DCIS and IDC were se-
lected for this study (Table 1). The median age of the 
patients was 60 years (range 36-78 years). The average 
tumor  size  was  2.3  cm  (range  0.5-15  cm).  Axillary 
lymph  node  metastases  were  detected  in  eight  pa-
tients. The histological grades for IDCs were I in three 
tumors (15%), II in eight tumors (40%), and III in nine 
tumors (45%). Ten tumors were positive for hormone 
receptors (HRs), estrogen receptor (ER), and/or pro-
gesterone receptor (PR) and were negative for HER2 
(HR+/HER2-). Seven tumors were HR/HER2+, two 
tumors  were  HR-/HER2+,  and  one  tumor  was 
HR/HER2-. The median percentage for the Ki67 pro-
liferation  index  was  13%  for  IDC  tumors  (range 
5-80%) and atypical nuclei coincided with the invasive 
and in situ component. The DCIS fraction of tumors 
was greater than10% in 15 samples and comedo ne-
crosis was detected in five cases. HER2 was overex-
pressed in 11 DCIS samples. The median Ki67 index of 
DCIS was of 7% (range 3-40%) and only eight cases 
had a Ki67 greater than 20%. 
Comparative micro array analysis and hierar-
chical clustering of IDC-DCIS matched sam-
ples 
IDC and DCIS paired samples from the 20 tu-
mors  were  hybridized  to  the  10,945  spots  on  the 
GeneChip®  Human  Gene  1.0  ST  Arrays  and  1,158 
probe sets were found to be differentially regulated. 
After adjusting the P values, we found that 56 genes 
were  differentially  expressed  in  the  IDC  samples. 
Among  these  genes,  31  were  upregulated  in  IDC 
samples compared to DCIS samples (Supplementary 
Material:    Table  S1)  and  25  were  downregulated 
(Supplementary Material:  Table S2).  
Hierarchical clustering was performed using the 
Euclidian  distance-generating  function  with  probe 
sets differentially expressed in the microarray analy-
sis (14). Our results showed that tumor samples were  Journal of Cancer 2012, 3 
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distributed into two well-differentiated clusters. The 
first cluster was composed of HR+/HER2- IDCs with 
the exception of one HER2+ tumor. The second cluster 
was composed mainly of DCIS samples, but also in-
cluded five HR-/HER2+ grade II IDC tumors and one 
HR-/HER”- sample.  
Interaction of tumor cells with stroma is re-
quired for tumor invasion 
Functional annotation of the differentially regu-
lated probe sets according to Gene Ontology revealed 
that several genes were upregulated in IDC compared 
with DCIS. These genes were involved in a) extracel-
lular  matrix  interactions  and  focal  adhesions 
(COL11A1,  COL10A1,  FN1,  COL12A1,  MMP13, 
THBS2, SPARC, LRRC15, and ASPN), b) cell adhesion 
(GJB2),  c)  extracellular  matrix  remodelling  and  cell 
motility  (PLAUR,  PLAU,  MMP11,  and  MMP14),  d) 
calcium  and  metal  binding  and  transport  (GPC6, 
ADAMTS16, and BGN), most of which are members of 
the  small  proteoglycans  family,  e)  genes  encoding 
signal  transducers  (RGS16,  ADORA3,  PRR5L,  and 
SPSB1),  and  f)  enzymes  involved  in  tumor  growth 
(ENNP2 and ST6GAL2).  
In contrast, 25 genes were statistically downreg-
ulated in IDC compared to DCIS. Functions of these 
genes included a) metabolic and enzymatic functions 
(ACACB  and  PAMR1),  b)  tumor  suppression 
(SERPINB5),  c)  cell  cytoskeleton  regulation  (KRT5), 
and d) cell adhesion (LYVE1, TNXB, TNXA, and F8).  
Confirmation of differential gene expression 
between IDC and DCIS via qRT-PCR  
The expression of several genes that were shown 
to be upregulated in IDC compared to DCIS in the 
microarray  analyses  were  further  analyzed  by 
qRT-PCR (Table 3). Our results confirmed the upreg-
ulation  of  ASPN,  GJB2,  ST6GAL2,  ENPP2,  and 
TMSB10  (P  <  0.05),  whereas  KRT5  (P  <  0.05)  was 
downregulated in IDC compared to DCIS. When the 
analysis was performed in the group of HR+/HER2- 
tumors,  the  upregulation  of  ASPN,  GJB2,  and 
ST6GAL2 was confirmed in IDC (P < 0.05), but the 
differential expression of ENPP2 and TMSB10 was not 
significant. Therefore, ENPP2 and TMSB10 were ex-
cluded from further analyses. Invasive HR+/HER2+ 
carcinomas were differentiated from DCIS by elevat-
ed expression levels of SERPINB5. However, this gene 
was not differentially expressed in the overall analy-
sis. As seen in Figure 1, there were great differences in 
mRNA  expression  of  asporin,  GJB2,  and  ST6GAL2 
between the samples of DCIS associated with IDC and 
the  samples  of  DCIS  without  invasion.  Differential 
expression  of  these  genes  was  not  detected  in  the 
comparison between normal tissues and pure DCIS.  
Immunohistochemical expression of ASPN 
(asporin), GJB2 (connexin 26) and ST6GAL2  
To further validate our gene expression data, we 
performed an immunohistochemical study to deter-
mine the protein expression patterns of ASPN, GJB2, 
and ST6GAL2 on TMAs of the tumors. There was in-
tense asporin nuclear staining in approximately 50% 
of DCIS tumor cell nuclei (range 20-100; SD = 27.4), 
51.5%  of  IDC  tumor  nuclei  (range  5-100;  SD  =  33), 
whereas  only  4%  of  nuclei  were  stained  in  normal 
tissues (P < 0.001). Asporin staining was also present 
in nuclei of fibroblast, endothelial cells, and mature 
lymphocytes (Figure 1).  
Positive  cytoplasmic  staining  of  connexin  26 
(GJB2 gene product) was found in 18/20 IDC samples, 
16/20  DCIS  samples,  and  only  2/20  normal  breast 
tissue samples (P = 0.001). Connexin 26 was also pre-
sent  in  fibroblasts,  endothelial  cells,  and  the  cyto-
plasm  of  mature  histiocytes  (Figure  1).  However, 
ST6GAL2  protein  immunostaining  was  heterogene-
ous and irregular in IDC and DCIS samples and neg-
ative in normal ductal breast epithelial cells. Positive 
controls included fibroblasts and endothelial cells.  
qRT-PCR analysis of gene expression in mouse 
tumors 
To  analyze  the  expression  of  genes  potentially 
associated with invasiveness, we utilized frozen ma-
terials  from  a  spontaneous  murine  model  of  breast 
cancer  (MMTV-PyMT).  Gene  expression  was  evalu-
ated by qRT-PCR. mRNA was obtained from tumors 
at  8  weeks  (equivalent  to  the  DCIS  stage)  and  13 
weeks (equivalent to the IDC stage) (15). The level of 
GJB2 was 134-fold higher  in the DCIS samples and 
37-fold higher in IDC tumors (P < 0.05) with respect to 
normal mouse breast tissue. However, no significant 
differences  were  found  between  the  DCIS  and  IDC 
samples.  Furthermore,  no  differences  in  ASPN  and 
ST6GAL2 levels were found (P = NS) (Figure 2). These 
analyses were repeated three times before validation. 
DISCUSSION 
The  two  main  pathological  hallmarks  of  neo-
plasia are local invasion and distant metastasis. The 
mechanisms of local invasion in breast DCIS and the 
progression  to  IDC  are  not  well  known.  Thus,  we 
compared gene expression patterns in simultaneous 
in situ and invasive areas of ductal carcinomas with 
the aim of elucidating the mechanism of breast carci-
noma invasiveness.   Journal of Cancer 2012, 3 
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The  classical  multistep  model  of  breast  cancer 
progression  hypothesized  that  IDC  is  preceded  by 
DCIS, “atypical ductal hyperplasia”, and “usual duc-
tal  hyperplasia”  (16).  Later,  it  was  suggested  that 
low-grade DCIS tends to progress to low grade IDC 
and, in parallel, high-grade DCIS tends to progress to 
high-grade  IDC  (17).  Simultaneous  assessments  of 
multiple  biological  markers  in  DCIS  and  IDC,  in-
cluding steroid receptors, HER-2, and cell cycle regu-
latory genes (p53, Ki-67, bcl-2, and p21) support this 
assessment  (18).  Nevertheless,  these  results  did  not 
improve the predictive power of standard pathologi-
cal parameters, nor did they explain the mechanism of 
invasiveness because the genetic changes that modu-
late  invasiveness  are  likely  already  present  in  cells 
before the cells acquire the typical DCIS morphology 
(2-4).  Recent  chromosomal,  genetic,  and  molecular 
studies support the theory of parallel disease for the 
progression of DCIS to IDC. However, it is likely that 
only a small subpopulation of highly tumorigenic and 
migrating cancer cells (0.1-3% of the total cancer cells) 
may be responsible for tumor growth, distant metas-
tases, treatment resistance, and recurrence (2-4).   
 
Figure 1. Expression of ASPN, GJB2, ENPP2, ST6GAL2, and TMSB10 genes. (A) Histograms showing differential gene expression be-
tween DCIS pure vs normal tissue, DCIS associate to IDC vs normal breast tissue, IDC vs normal tissue, DCIS associate to IDC vs DCIS 
pure samples and IDC vs DCIS pure samples. Gene expression levels of ASPN, GJB2, ENPP2, ST6GAL2 and TMSB10 were determined by 
qRT-PCR. The bar represents the mean ± S.E. of all samples by duplicate. Asterisks (*) indicates statistically significant differences (P < 
0.05). (B) Immunohistochemical images of asporin and GJB2 (connexin-26) expressions in normal tissue (black arrow), proliferative 
non-invasive (two black arrows) and invasive neoplasms (black star).   Journal of Cancer 2012, 3 
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Figure 2. Microscopic images and qRT-PCR of mice tumors. (A) Microscopic images of typical breast tissue in MMTV-PyMT mice 
at ages of 0 weeks (considered as normal tissue), 8 weeks (equivalents to DCIS), and in 13 weeks (equivalent to IDC). Tumor proliferation 
overgrowth stroma with the time as the grade of nuclear atypia increases. Mitoses are clearly found in IDC (see arrow), H&E staining, x40 
magnification. (B) Histograms showing relative fold changes in gene expression by qRT-PCR of ASPN, GJB2, and ST6GAL2. Significative 
increased overexpression of GJB2 in DCIS and IDC with respect to normal tissue. Each bar represents the mean ± S.E. of all samples by 
duplicate. Asterisk (*) denote statistically significant differences (P < 0.05). 
 
 
 
Table 3. Validation of microarray-based gene expression results by qRT-PCR. 
  IDC vs. DCIS  Total IDC vs. DCIS  
(n = 20) 
HR+/HER-2-  
(n = 10) 
HR+/HER-2+  
(n = 7) 
Gene Name, symbol  Average FC*± SE  Mean FC  P  Mean FC  P  Mean FC  P 
Asporin , ASPN  3.336 ± 0.625  5.371  0.001  5.586  0.034  1.627  N.S. 
Maspin, SERPINB5  0.772 ± 0.114  0.949  N.S.  0.827  N.S.  6.732  <0.001 
Connexin 26, GJB2  1.1635 ± 0.181  5.276  0.001  3.088  0.007  1.651  N.S. 
Autotaxin,  ENPP2  1.019 ± 0.138  6.440  0.013  2.405  N.S.  2.548  N.S. 
ST6GAL2  1.493 ± 0.141  16.547  <0.001  13.026  0.002  2.952  N.S. 
Thymosin beta-10, TMSB10  1.075 ± 0.063  5.017  0.048  1.203  N.S.  1.797  N.S. 
Cytokeratin 5, KRT5  0.689 ± 0.106  0.385  0.004  0.492  N.S.  0.076  N.S. 
Notes: * Data from microarray analysis. Abbreviations: FC, fold-change; N.S., non-significant; HR, hormone receptors (including estrogen 
and progesterone receptors) 
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Breast tumor cell invasiveness is a complex pro-
cess that is related to genetic alterations of tumor cells, 
loss of myoepithelial cells, and a stromal facilitation of 
invasion  that  includes  fibroblast  activation,  altered 
expression of growth and angiogenic factors, immu-
nological  reactivity,  and  increased  expression  of 
chemokines  and  matrix  metalloproteinases  (MMPs) 
(4,  19-21).  Many  studies  have  analyzed  the  role  of 
myoepithelial  cells  in  blocking  tumor  cell  invasive-
ness (3, 4, 7), which is not the subject of our study. 
Myoepithelial cells may compete with fibroblasts and 
with the inflammatory processes, which could facili-
tate invasion (4, 19, 21). 
Previous  transcriptome  studies  underlines  the 
cooperation of the stroma in breast carcinoma inva-
sion, which is associated with upregulation of EMT, 
cell motility, extracellular matrix (ECM) degradation, 
and  cell  proliferation,  whereas  genes  related  to  cell 
adhesion and cytoskeletal intermediate filaments are 
generally downregulated (2, 4, 7, 8). Our results are in 
agreement  with  the  upregulation  of  several  genes 
related to the extracellular matrix (MMP11, MMP13, 
MMP14, SPARC, LLCR15, PLAU, and ASPN) and cell 
adhesion (GJB2) in breast carcinomas. We selected one 
gene from each category to further explore their func-
tions in these metabolic pathways.  
Several extracellular matrix proteins may favor 
invasiveness and their production may be stimulated 
by growth factors such as transforming growth factor 
beta (TGF-), which is controlled by several proteases, 
especially MMPs (20). The expression of TGF- family 
members  was not significantly altered in our study 
despite their well-documented role in invasiveness (2, 
3, 8, 9) whereas we did observe upregulation of MMPs 
and asporin, which are involved in the TGF- regula-
tion. Asporin, encoded by ASPN, is a member of the 
leucine-rich  repeat  protein  family  that  is  associated 
with mesenchymal tissues (22). Asporin is produced 
by fibroblasts, inhibits TGF- effects, and has a para-
crine effect on prostate (23) and stomach (24) tumor 
cells.  Although  asporin  was  previously  associated 
with invasive lobular carcinomas (25), we found that 
it  has  an  important  role  in  initial  carcinogenesis 
(DCIS)  and  in  invasiveness  of  IDC.  In  the  present 
work, the level of asporin mRNA in IDC, as deter-
mined by qRT-PCR, was related to invasiveness and 
the expression of this protein was confirmed by im-
munohistochemistry in hormone-related cases of IDC 
and DCIS. In contrast, the activity of decorin, another 
member of the ASPN family of genes is controversial. 
Decorin  expression  has  been  correlated  with  poor 
prognosis in estrogen receptor-negative breast cancers 
(26). Other studies have indicated an inhibitory effect 
by decorin on both primary tumor growth and meta-
static spreading (27). 
The upregulation of genes related to cell adhe-
sion in carcinomas, such as GJB2, is unexpected be-
cause neoplasms are characterized by loss of cell co-
hesion.  GJB2  encodes  connexins  26  and  43,  which 
participate in specialized structures on plasma mem-
branes  by  contacting  adherent  cells  and  forming 
cell-to-cell  channels.  In  other  tumors,  such  as  colo-
rectal carcinomas, the prognostic significance of con-
nexin 26 is controversial (28, 29). In breast cancer cell 
cultures the downregulation of connexin 26 is associ-
ated with EMT inhibition (30). More recent studies of 
human breast carcinomas have shown an association 
of connexin 26 expression with invasion and lymph 
node metastases (31). Our transcriptome studies in-
dicated that GJB2 upregulation correlated with inva-
sion and increased GJB2 mRNA production was de-
tected by qRT-PCR. Connexin 26 was also identified 
by  immunohistochemistry  in  tumor  cells  and  in 
stroma. Furthermore, a statistical association of GJB2 
upregulation with DCIS was demonstrated in PyMT 
mouse samples, thus supporting its role in DCIS as-
sociated  with  IDC  and  pure  IDC,  but  not  in  pure 
DCIS.  
Invasion is a multi-step process in which a mul-
tidirectional cross talk of tumor cells and  stroma is 
modulated by paracrine signals coming from associ-
ated  tumor-stroma  and/or  inflammatory  processes. 
Our  study  confirmed  that  expression  of  ASPN  and 
GJB2  occurs  very  early  during  carcinogenesis  and 
may be related to the initiation of invasion and tumor 
dissemination. Further studies are required to confirm 
our data. These data would assist in the development 
of precise diagnostic markers of invasion and in the 
identification of new therapeutic targets.  
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